These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12403370)

  • 1. Immunobiology of tumor necrosis factor receptor superfamily.
    Zhou T; Mountz JD; Kimberly RP
    Immunol Res; 2002; 26(1-3):323-36. PubMed ID: 12403370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
    Kajiwara K; Saito A; Ogata S; Tanihara M
    Biochim Biophys Acta; 2004 Jun; 1699(1-2):131-7. PubMed ID: 15158720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
    Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
    Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A family of ligands for the TNF receptor superfamily.
    Cosman D
    Stem Cells; 1994 Sep; 12(5):440-55. PubMed ID: 7528588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules.
    Choi YJ; Baranowska-Daca E; Nguyen V; Koji T; Ballantyne CM; Sheikh-Hamad D; Suki WN; Truong LD
    Kidney Int; 2000 Oct; 58(4):1481-91. PubMed ID: 11012883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.
    Tsai HF; Lai JJ; Chou AH; Wang TF; Wu CS; Hsu PN
    Arthritis Rheum; 2004 Feb; 50(2):629-39. PubMed ID: 14872508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines.
    Phillips TA; Ni J; Hunt JS
    Placenta; 2001; 22(8-9):663-72. PubMed ID: 11597186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrocyte targets and effectors of autoimmunity: a role for death receptors?
    Hammond LJ; Palazzo FF; Shattock M; Goode AW; Mirakian R
    Thyroid; 2001 Oct; 11(10):919-27. PubMed ID: 11716038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
    Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
    Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.
    Jelinek DF; Darce JR
    Curr Dir Autoimmun; 2005; 8():266-88. PubMed ID: 15564725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma.
    Choi C; Park JY; Lee J; Lim JH; Shin EC; Ahn YS; Kim CH; Kim SJ; Kim JD; Choi IS; Choi IH
    J Immunol; 1999 Feb; 162(4):1889-95. PubMed ID: 9973455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation.
    Bachmann F; Buechner SA; Wernli M; Strebel S; Erb P
    J Invest Dermatol; 2001 Jul; 117(1):59-66. PubMed ID: 11442750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases.
    Nardelli B; Moore PA; Li Y; Hilbert DM
    Leuk Lymphoma; 2002 Jul; 43(7):1367-73. PubMed ID: 12389615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.
    Gruss HJ
    Int J Clin Lab Res; 1996; 26(3):143-59. PubMed ID: 8905447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.
    Martínez-Lorenzo MJ; Anel A; Gamen S; Monle n I; Lasierra P; Larrad L; Piñeiro A; Alava MA; Naval J
    J Immunol; 1999 Aug; 163(3):1274-81. PubMed ID: 10415024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
    Thomas WD; Hersey P
    J Immunol; 1998 Sep; 161(5):2195-200. PubMed ID: 9725211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.